论文部分内容阅读
目的:观察β-受体阻滞剂倍他乐克治疗慢性顽固性充血性心力衰竭(CHF)的临床疗效及安全性。方法:将60例病因不同的患者随机分为两组,对照组按常规抗心力衰竭治疗,包括休息、低盐饮食、吸氧、应用血管紧张素转换酶抑制剂(ACEI)、洋地黄、利尿剂、抗心律失常、消除心力衰竭诱因等综合措施。治疗组在对照组的基础上给予倍他乐克,治疗6周后观察心力衰竭患者心率、血压和心功能的变化,比较治疗前后上述指标的差异,以评估其临床疗效及安全性。结果:应用倍他乐克后心力衰竭患者心功能分级显著改善,心率明显降低,收缩压及舒张压也显著降低。结论:在常规抗心力衰竭药物治疗基础上加用β受体阻滞剂可明显改善慢性心力衰竭患者的心功能,提高生活质量,延长患者寿命。
Objective: To observe the clinical efficacy and safety of β-receptor blocker Betaloc in the treatment of chronic intractable congestive heart failure (CHF). Methods: Sixty patients with different etiology were randomly divided into two groups. The control group was treated with conventional anti-heart failure, including rest, low-salt diet, oxygen inhalation, application of angiotensin-converting enzyme inhibitor (ACEI), digitalis, Agents, anti-arrhythmia, eliminate heart failure incentives and other comprehensive measures. The treatment group was given Betaloc on the basis of the control group. After 6 weeks of treatment, the changes of heart rate, blood pressure and heart function in patients with heart failure were observed. The differences of the above indexes before and after treatment were compared to evaluate the clinical efficacy and safety. Results: After the application of metoprolol, heart function scores of patients with heart failure were significantly improved, heart rate was significantly reduced, systolic blood pressure and diastolic blood pressure were also significantly lower. Conclusion: The addition of β-blockers to conventional anti-heart failure drug therapy can significantly improve cardiac function, improve quality of life and prolong patient’s life in patients with chronic heart failure.